Summary of retrospective studies on the efficacy of benralizumab in patients with EGPA
| Study | Cases, n | Benralizumabdose | Observationperiod | OCS doses | OCS discontinuation | Symptom | Remission | Relapse |
|---|---|---|---|---|---|---|---|---|
| Cottu A et al. [20] | 68 | 30 mgq4–8w | - | - | 38% | - | 11% | 49% |
| Bettiol A et al. [21] | 121 | 30 mgq4–8w | 12 months | - | - | - | 19% | 46% |
| Nanzer A et al. [22] | 70 | 30 mgq4–8w | 24 months | ↓ (75%) | 68% | ↓ (BVAS) | 15% | 67% |
OCS: oral corticosteroid; BVAS: Birmingham Vasculitis Activity Score; q4–8w: every 8 weeks (first three doses given 4 weeks apart); ↓: reduction; -: no data